Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with NK Cells in Advanced Cancer
NCT03554889Phase 1Unknown
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Antibody Conjugates, Lymphokine-Activated Killer Cells, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nimotuzumab and troculeucel in cancer. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Status: unknown.
02
Drugs
nimotuzumabtroculeucel
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03554889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554889.